Blink Device Company Receives CE Mark for TwitchView™ Quantitative Monitor for Neuromuscular Blockade

SEATTLE, WA June 1, 2018 - Blink Device Company announced today that it has received a CE Mark for TwitchView, its novel, user-friendly, quantitative monitor for neuromuscular blockade. With this certification, the company plans to launch the product into the European market, first appearing at the 2018 European Society of Anaesthesiology Annual Meeting in Copenhagen this weekend.  

The current standard of care for monitoring neuromuscular blockade during surgery is peripheral nerve stimulation coupled with observation or accelerometry, technology that has not been improved for decades. TwitchView brings the assessment of neuromuscular blockade into the 21st century with reliable and accurate real-time electromyography-based monitoring that can support better drug dosing decisions and reversal timing—helping prevent residual neuromuscular blockade.  

“At Blink Device Company, we aim to identify areas in medicine that can greatly benefit from technological innovation” said CEO Justin Hulvershorn, M.D, Ph.D.  “Neuromuscular blockade is ripe for such an advance. A typical response from clinicians who have used TwitchView is that it is like ‘turning on the lights in a dark room’. With remarkable ease-of-use, updating practices to benefit both practitioners and their patients is nearly effortless.”